Your SlideShare is downloading. ×
Chemotherapy induced lung toxicity dr. varun
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.


Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

Chemotherapy induced lung toxicity dr. varun


Published on

Published in: Health & Medicine

  • Be the first to comment

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide
  • KL-6) is a mucinlike high-molecular-weight glycoprotein expressed by type II alveolar pneumocytes
  • poorlydefined centrilobular nodules (arrows) and extensiveareas of ground-glass attenuation
  • Transcript

    • 1. ChemotherapyInduced LungDiseaseDr. Varun GoelRajiv gandhi cancer institutedelhi
    • 2. Drug Induced Lung Disease Drug induced lung disease is increasing being recognized with over 150 drugs described as causing adverse pulmonary reactions.  In the 1960s, the first drug reported to induce chemotherapy-related lung disease was busulfan. All parts of the respiratory system can be affected. Overall, less than 10% of patients who receive chemotherapeutic agents develop pulmonary toxicities
    • 3. Chemotherapeutic Agents
    • 4.  Sign and symptoms  symptoms may occur acutely or insidiously  cough, fever, dyspnea  Crackles.  PFT- ↓ DLCO
    • 5. Problems in Recognition Drugs are given as part of multidrug regimens and offending agent may not be clear Other conditions, such as pulmonary infection, pulmonary thromboembolic disease or progression of cancer, occur considerably more frequently No pathognomonic clinical, radiographic or pathologic findings New agents or new combinations are frequently being used and unrecognized or new types of toxicity occur.
    • 6. Recognition High index of suspicion Knowledge of patterns of toxicity associated with drugs Exclusion of other likely entities
    • 7.  Laboratory Findings ↑ TLC, ESR and CRP  ↑Serum Krebs von den Lunge-6 (KL-6)  expressed by type II alveolar pneumocytes  may be useful for ruling out other causes of pneumonitis.
    • 8.  Radiologic Findings  HRCT –findings are not specific.  Interstitial, alveolar, or mixed infiltrative patterns  Pleural effusion with or without parenchymal lung disease  Lymphadenopathy is typically not present
    • 9.  Bronchoalveolar lavage  several studies reported the presence of a characteristic or predominant cells associated with particular drugs but results are variable.  Useful to exclude atypical or typical infections. Histologic Findings  not mandatory, cannot confirm the diagnosis  it helps support it and can exclude other diseases  may show diffuse alveolar damage, organizing pneumonia, nonspecific pneumonitis, or neutrophilic alveolitis
    • 10. Patterns of Toxicity  Interstitial pneumonitis/fibrosis  Hypersensitivity pneumonitis  Non cardiac pulmonary edema  Acute pneumonia
    • 11. Patterns of ToxicityInterstitial Pneumonitis/ Fibrosis Acute pneumonia Bleomycin Mitomycin/Vinca Mitomycin C Gefinitib Busulfan Cyclophosphamide CarmustineHypersensitivity Pneumonitis Capillary leak/edema Methotrexate Retinoic Acid Paclitaxel Gemcitabine Cytosine Arabinoside
    • 12. Interstitial Pneumonitis/Fibrosis Presentation is subacute to chronic Dyspnea and dry cough Bibasilar crackles Radiographs show increased marking, peripherally/ bases can progress to honeycombing
    • 13. Intersitial Pneumonitis/Fibrosis Histopathology shows areas of fibrosis and varying degrees of mononuclear cell infiltration Atypical type II pneumocytes are present
    • 14. Chemotherapeutic Drugs Interstitial Fibrosis Pattern Bleomycin Cyclophosphamide Mitomycin BCNU Busulfan gemcitabine, fludarabine, paclitaxel, docetaxel, irinotecan, gefitinib, imatinib, bortezomib, methotrexate, 6- mercaptopurine, oxaliplatin, thalidomide, azathioprine
    • 15. Interstitial Pneumonitis/Fibrosis Mechanism of Toxicity BAL in animals and humans in bleomycin induced show increased number of neutrophils and in some cases eosinophils (similar to IPF) Direct toxicity with imbalance in oxidant - antioxidant systems Vascular damage with influx of inflammatory cells and fibroblasts; induction of cytokines Increased TGF- Beta Imbalance between the protease and antiprotease system
    • 16. •Bleomycin induces reactive oxygen radicals by forming a complex with Fe3+• Iron chelators ameliorate the pulmonary toxicity of bleomycin inanimal models
    • 17.  Incidence of toxicity is 4% but subclinical toxicity based on PFTS is 25% Bleomycin hydrolase - major enzyme responsible for metabolism  lung and skin have the lowest levels of the enzyme  most common targets for bleomycin toxicity
    • 18. Bleomycin Toxicity Risk Factors Dose > 450 units, although toxicity can occur at any dose Radiation to thorax Supplemental oxygen – no safe threshold Age >70 years Elevated Creatinine ? Use of GCSF  animal studies suggest GCSF t/t is associated with bleomycin-induced pulmonary toxicity  data in humans are conflicting
    • 19.  Some data suggest that continuous infusion of bleomycin may be associated with less pulmonary toxicity than bolus therapy; however, these data are inconclusive
    • 20. Bleomycin Pulmonary Toxicity Interstitial fibrosis most common, rare hypersensitivity pneumonitis Treatment involves no further drug, possible corticosteroids, avoidance of oxygen/radiation if possible Late exacerbations can occur
    • 21. Cyclophosphamide MOA- reactive oxygen species. Endothelial swelling; pneumocyte dysplasia; lymphocytic and histiocytic infiltration; fibrosis. bibasilar reticular pattern; <1% incidence; no direct dose dependence Drug withdrawal; corticosteroids may be
    • 22. Hypersensitivity Pneumonitis Acute to subacute presentation with systemic symptoms fever, fatigue, arthralgia – dyspnea and cough may be late Eosinophilia may be present Radiographs show air space disease
    • 23. Hypersensitivity PneumonitisHistopathology shows1) eosinophils inalveoli and interstitium(Loffler’s syndrome) or2) mixed mononuclearcell infiltrates witheosinophils, looselyformed granulomas
    • 24. Chemotherapy DrugsHypersensitivity Pneumonitis Methotrexate Paclitaxel Docetaxel imatinib, cyclophosphamide, nitrogen mustards, busulfan, bleomycin, fludarabine, rituximab, temozolomide
    • 25. Methotrexate Toxicity Usually presents with malaise, myalgias, fever, cough and dyspnea, skin rash in some cases Radiographs vary from normal to mild atelectasis to bilateral alveolar infiltrates: Gallium scans are positive Dramatic response to corticosteroids Seldom leads to fibrosis
    • 26. Methotrexate PneumonitisMechanism of Toxicity Immunological mechanism, supported by BAL findings and dramatic response to steroids lymphocytic alveolitis is a consistent finding in methotrexate pneumonitis  imbalance of the CD4-to-CD8 ratio
    • 27. Taxanes Paclitaxel  Associated with hypersensitivity reaction during infusion with dyspnea, bronchospasm, urticaria, rash and hypotension ( up to 1/3 patients)  suspension vehicle (Cremophor El) causes, not the drug.  Premed with steroids, antihistamines and H2 blockers ameliorates( 1% incidence) Docetaxel - Little data
    • 28. Paclitaxel Pulmonary ToxicitySyndromes Dyspnea during infusion – common Hypersensitivity pneumonitis –  Subacute development of dyspnea  CT scans show transient ground glass infiltrate or interstitial infiltrates  Usually resolves spontaneously or with corticosteroids Rare presentations of acute pneumonia/intersitial fibrosis
    • 29. Non Cardiac Pulmonary Edema Respiratory distress occurs over several hours  Subacute capillary leak syndrome Can be associated with effusions and edema Radiographs show diffuse bilateral alveolar filling densities Usually responds to withdrawal of offending drug Found with gemcitabine/ATRA
    • 30. Non Cardiac Pulmonary Edema  Alltrans retinoic acid  Gemcitabine  Cytarabine ( ARA C) Imatinib, azathioprine, G-CSF, IL-2, MMC, nitrogen mustards, paclitaxel, interferon α, pentostatin, decitabine, vinorelbine
    • 31. ATRAAll trans retinoic acid Fluid overload develops with weight gain, peripheral edema, pleural effusion Patients present with dyspnea and edema and usually weight gain. Increased risk with elevated WBC Can be treated with corticosteroids.
    • 32. Gemcitabine Dyspnea reported in up to 10% with severe dyspnea in 5% -Self limited – Acute hypersensitivity with bronchospasm – Capillary leak Infiltrates – subtle capillary leak to interstitial infiltrate to pulmonary edema picture – Usually responds to holding drug or giving steroids
    • 33. Acute Pneumonia Syndrome similar to non cardiac pulmonary edema – Respiratory distress develops over several hours – Bilateral interstitial-alveolar infiltrates Improvement but persistent pulmonary abnormalities persist Pathology studies show inflammatory cells with endothelial inflammation as well as vascular leak
    • 34. Acute Pneumonia Syndrome  Mitomycin -Vinca alkaloid reaction  Gefitinib Erlotinib, imatinib, gemcitabine, temsirolimus, everolimus, thalidomide, taxanes, bortezomib, irinotecan, procarbazine, piritrexim, temozolomide, trastuzumab, cetuximab, pemetrexed
    • 35. Mitomycin-Vinca AlkaloidReactions Syndrome of acute dyspnea without other respiratory symptoms within hours of receiving vinca alkaloid in patients on mitomycin Respiratory failure can occur Treated with supportive care and combinations of diuretics, bronchodilators and corticosteroids Improvement occurs but chronic toxicity occurs
    • 36. Gefitinib Main toxicity is mild acne like rash and limited diarrhea Interstitial lung disease has been reported which can be serious – up to 2%  Unclear mechanism  augmentation of pulmonary fibrosis by decreasing EGFR phosphorylation resulting in a decrease in regenerative epithelial proliferation
    • 37.  Diffuse ground glass opacities have been observed on CT imaging
    • 38. Bevacizumab Recombinant humanized monoclonal antibody targets vascular endothelial growth factor (VEGF) – Approved for colorectal cancer; under study for breast cancer, renal cancer and lung cancer Side effects – Thromboembolic events – Hypertension – Hemorrhage – Gastrointestinal perforation
    • 39.  Serious tumor related bleeding with hemoptysis /hematemesis in 6 cases, all with centrally located pulmonary tumors close to major blood vessels. (Clin Res Cancer 2004; 10: 4258S)
    • 40. Imatinib/Dasatinib Mechanism of Injury- Unknown  one case of imatinib Hypersensitivity suggested by high number of lymphocytes with low CD4/CD8 ratio Exudative pleural effusion/pulmonary edema; eosinophilic infiltration; interstitial inflammation/fibrosis
    • 41. M-TOR INHIBITORS Sirolimus  Possibly evoking Th1 response and recruitment of an inflammatory response in lung.  BOOP, lymphocytic alveolitis  5%-15% incidence  Risks factors include late switch to drug and/or renal impairment. Temsirolimus/Everolimus  .5%–5% incidence
    • 42. - Thank u…..